https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-first-location-boston BiopharmaWatch en 2026-10-07T15:00:00.000Z CVS Pharmacy® celebrates opening of first pharmacy-focused location in Boston area https://www.biopharmawatch.com/news/ASTH/alignment-health-expands-california-2027 BiopharmaWatch en 2026-10-07T15:00:00.000Z Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027 https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-trial-update-danon-disease BiopharmaWatch en 2026-10-07T13:36:00.000Z Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar https://www.biopharmawatch.com/news/AMN/amn-healthcare-q3-2026-earnings-call BiopharmaWatch en 2026-10-07T13:15:00.000Z AMN Healthcare to Hold Third Quarter 2026 Earnings Conference Call on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AIM/aim-immunotech-strategy-pancreatic-cancer BiopharmaWatch en 2026-10-07T13:14:00.000Z AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-acquires-nexdine-hospitality BiopharmaWatch en 2026-10-07T13:00:00.000Z Healthcare Services Group Announces Acquisition of NEXDINE Hospitality https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-momentum-federal-initiative BiopharmaWatch en 2026-10-07T13:00:00.000Z Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease https://www.biopharmawatch.com/news/TXG/10x-genomics-fred-hutch-collaboration-cancer-research BiopharmaWatch en 2026-10-07T13:00:00.000Z 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers https://www.biopharmawatch.com/news/BCDA/biocardia-presents-cardiamp-hf-ii-trial-design BiopharmaWatch en 2026-10-07T13:00:00.000Z BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting https://www.biopharmawatch.com/news/OPTH/optimi-health-thinkequity-conference-2026 BiopharmaWatch en 2026-10-07T13:00:00.000Z Optimi Health to Present at the ThinkEquity Conference https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-bio-europe-2026-presentation BiopharmaWatch en 2026-10-07T12:48:00.000Z Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-07T12:45:00.000Z Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/CMND/clearmind-advances-dialogue-federal-government-psychedelic-therapies BiopharmaWatch en 2026-10-07T12:40:00.000Z Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA https://www.biopharmawatch.com/news/LTRN/lantern-pharma-taiwan-approvals-phase-2-trial-lp-300 BiopharmaWatch en 2026-10-07T12:31:00.000Z Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC https://www.biopharmawatch.com/news/OSTX/usda-feedback-ost-her2-canine-osteosarcoma BiopharmaWatch en 2026-10-07T12:30:00.000Z OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma https://www.biopharmawatch.com/news/QTI/qt-imaging-breast-acoustic-ct-scanner-premier-agreement BiopharmaWatch en 2026-10-07T12:30:00.000Z QT Imaging’s Breast Acoustic CT™ Scanner Now Available Through National Group Purchasing Agreement with Premier https://www.biopharmawatch.com/news/DXCM/dexcom-q3-2026-earnings-release-call BiopharmaWatch en 2026-10-07T12:30:00.000Z Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-david-liu-cmo BiopharmaWatch en 2026-10-07T12:30:00.000Z Vir Biotechnology Appoints David Liu as Chief Medical Officer https://www.biopharmawatch.com/news/WGS/genedx-advances-genomic-newborn-screening-icoms-2026 BiopharmaWatch en 2026-10-07T12:30:00.000Z GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026 https://www.biopharmawatch.com/news/MRNA/tempus-collaboration-moderna-merck-intismeran BiopharmaWatch en 2026-10-07T12:30:00.000Z Tempus Announces Multi-Year Collaboration with Moderna and Merck https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-application-glp1-peptides BiopharmaWatch en 2026-10-07T12:30:00.000Z FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body https://www.biopharmawatch.com/news/QTRX/alzpath-quanterix-licensing-agreement-alzheimers-research BiopharmaWatch en 2026-10-07T12:30:00.000Z ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research https://www.biopharmawatch.com/news/ABBV/abbvie-temab-a-breakthrough-therapy-designations BiopharmaWatch en 2026-10-07T12:30:00.000Z AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC https://www.biopharmawatch.com/news/HALO/halozyme-injunction-merck-keytruda-sc-europe BiopharmaWatch en 2026-10-07T12:30:00.000Z Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-pancreatic-cancer-data BiopharmaWatch en 2026-10-07T12:30:00.000Z Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib https://www.biopharmawatch.com/news/RNXT/renovorx-prism-tamp-trial-first-patient-enrolled BiopharmaWatch en 2026-10-07T12:30:00.000Z RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial https://www.biopharmawatch.com/news/ONMD/onemednet-signs-mediplexus-channel-partner-korea BiopharmaWatch en 2026-10-07T12:30:00.000Z OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region https://www.biopharmawatch.com/news/RARE/ultragenyx-sells-priority-review-voucher-210-million BiopharmaWatch en 2026-10-07T12:30:00.000Z Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-appoints-kaitlyn-tuson BiopharmaWatch en 2026-10-07T12:30:00.000Z Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-cliniquantum-quantum-analysis BiopharmaWatch en 2026-10-07T12:22:00.000Z SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture https://www.biopharmawatch.com/news/ICU/seastar-fda-breakthrough-device-designation-scd-therapy BiopharmaWatch en 2026-10-07T12:16:00.000Z FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-3-trials-nsclc BiopharmaWatch en 2026-10-07T12:15:00.000Z MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/CVS/cvs-health-mmr-vaccines-new-york-measles-outbreak BiopharmaWatch en 2026-10-07T12:10:00.000Z CVS Health® reminds New Yorkers that MMR vaccines are available statewide amid measles outbreak https://www.biopharmawatch.com/news/VIVS/vivosim-labs-fda-regulations-non-animal-testing BiopharmaWatch en 2026-10-07T12:05:00.000Z VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods https://www.biopharmawatch.com/news/LABT/lakewood-amendex-positive-preclinical-data-bisphosphocin BiopharmaWatch en 2026-10-07T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds https://www.biopharmawatch.com/news/QTRX/quanterix-innovita-ivd-access-china-approvals BiopharmaWatch en 2026-10-07T12:00:00.000Z Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals https://www.biopharmawatch.com/news/GEHC/ge-healthcare-third-quarter-2026-results BiopharmaWatch en 2026-10-07T12:00:00.000Z GE HealthCare to announce third quarter 2026 results on October 28, 2026 https://www.biopharmawatch.com/news/NTRA/natera-signatera-guided-study-melanoma BiopharmaWatch en 2026-10-07T12:00:00.000Z Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma https://www.biopharmawatch.com/news/LPCN/lipocine-health-canada-approval-tlando BiopharmaWatch en 2026-10-07T12:00:00.000Z Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy https://www.biopharmawatch.com/news/IMUX/immunic-present-new-data-vidofludimus-calcium-mstoronto2026 BiopharmaWatch en 2026-10-07T12:00:00.000Z Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-positive-data-mst2026 BiopharmaWatch en 2026-10-07T12:00:00.000Z Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 https://www.biopharmawatch.com/news/PCRX/pacira-caregiver-survey-postsurgical-recovery BiopharmaWatch en 2026-10-07T12:00:00.000Z Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home https://www.biopharmawatch.com/news/AKBA/akebia-investor-meetings-kidney-health-forum BiopharmaWatch en 2026-10-07T12:00:00.000Z Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-warrant-purchase-offer BiopharmaWatch en 2026-10-07T12:00:00.000Z Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants https://www.biopharmawatch.com/news/ARWR/arrowhead-fda-star-pilot-plozasiran BiopharmaWatch en 2026-10-07T11:30:00.000Z Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/KURA/caspian-kura-investor-webcast-ko-7246-data BiopharmaWatch en 2026-10-07T11:15:00.000Z Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes https://www.biopharmawatch.com/news/QDEL/quidelortho-appoints-sanjeev-sharma-investor-relations BiopharmaWatch en 2026-10-07T11:13:00.000Z QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations https://www.biopharmawatch.com/news/USNA/usana-partnership-university-utah-athletics BiopharmaWatch en 2026-10-07T11:06:00.000Z USANA Health Sciences and University of Utah Athletics Announce New Partnership https://www.biopharmawatch.com/news/KIDS/orthopediatrics-launches-knee-tractorfix-bracing BiopharmaWatch en 2026-10-07T11:05:00.000Z OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-upcoming-presentations-ms-data-mstoronto2026 BiopharmaWatch en 2026-10-07T11:05:00.000Z Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 https://www.biopharmawatch.com/news/GKOS/glaukos-third-quarter-2026-results-release BiopharmaWatch en 2026-10-07T11:00:00.000Z Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-phase-2a-trial-glyphago BiopharmaWatch en 2026-10-07T11:00:00.000Z Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-nanopulse-af-study-enrollment-target BiopharmaWatch en 2026-10-07T11:00:00.000Z Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-strengthens-ip-portfolio BiopharmaWatch en 2026-10-07T11:00:00.000Z Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States https://www.biopharmawatch.com/news/KOD/kodiak-sciences-aao-2026-presentation BiopharmaWatch en 2026-10-07T11:00:00.000Z Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 https://www.biopharmawatch.com/news/DHR/danaher-ai-autonomous-lab-launch BiopharmaWatch en 2026-10-07T11:00:00.000Z Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-strategic-process-cvkd BiopharmaWatch en 2026-10-07T11:00:00.000Z Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics https://www.biopharmawatch.com/news/BLLN/billiontoone-northstar-response-cancer-monitoring-study BiopharmaWatch en 2026-10-07T11:00:00.000Z BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-07T11:00:00.000Z Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 https://www.biopharmawatch.com/news/ARVN/arvinas-arv-102-parkinsons-phase-1-trial-data BiopharmaWatch en 2026-10-07T11:00:00.000Z Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease https://www.biopharmawatch.com/news/NVS/novartis-ms-innovation-remibrutinib-kesimpta-data BiopharmaWatch en 2026-10-07T11:00:00.000Z Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-fda-aligned-nams-strategy BiopharmaWatch en 2026-10-07T11:00:00.000Z VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy https://www.biopharmawatch.com/news/RMTI/rockwell-medical-best-workplaces-2026 BiopharmaWatch en 2026-10-07T10:26:00.000Z Rockwell Medical Ranked No. 16 on the 2026 Fortune ‘Best Workplaces in Manufacturing & Production’ List https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-nanets-2026-presentation BiopharmaWatch en 2026-10-07T10:16:00.000Z Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium https://www.biopharmawatch.com/news/EW/edwards-lifesciences-earnings-conference-call-november-2026 BiopharmaWatch en 2026-10-07T10:00:00.000Z Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 https://www.biopharmawatch.com/news/BSX/boston-scientific-appoints-joseph-fitzgerald-coo BiopharmaWatch en 2026-10-07T10:00:00.000Z Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer https://www.biopharmawatch.com/news/TDOC/teladoc-health-expands-solo-platform-ai-capabilities BiopharmaWatch en 2026-10-07T10:00:00.000Z Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery https://www.biopharmawatch.com/news/OCS/oculis-licaminlimab-aao-2026 BiopharmaWatch en 2026-10-07T06:00:00.000Z Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-phase-1b-2-study-bexobrutideg-cll BiopharmaWatch en 2026-10-07T05:00:00.000Z Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia https://www.biopharmawatch.com/news/PCVX/vaxcyte-public-offerings-common-stock-notes BiopharmaWatch en 2026-10-07T02:48:00.000Z Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-ai-cancer-risk-tool-launch BiopharmaWatch en 2026-10-07T02:32:39.000Z YD Bio and EG BioMed Launch AI Cancer Risk Assessment Tool Covering 10 Cancer Types https://www.biopharmawatch.com/news/NNVC/nanoviricides-presentation-niba-investment-conference-2026 BiopharmaWatch en 2026-10-07T00:00:00.000Z NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 https://www.biopharmawatch.com/news/HIMS/hims-hers-health-securities-fraud-class-action BiopharmaWatch en 2026-10-06T21:33:07.977Z Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower https://www.biopharmawatch.com/news/HYFT/mindwalk-ai-biological-context-layer BiopharmaWatch en 2026-10-06T20:47:00.000Z MindWalk (NASDAQ : HYFT) : l'IA d'entreprise a trouvé sa couche ontologique, la biologie en a besoin d'une ancrée dans la fonction biologique https://www.biopharmawatch.com/news/BLCO/bausch-lomb-advances-oral-treatment-dry-amd BiopharmaWatch en 2026-10-06T20:30:00.000Z Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting https://www.biopharmawatch.com/news/EHC/encompass-health-bangor-hospital-opening-maine BiopharmaWatch en 2026-10-06T20:30:00.000Z Encompass Health Rehabilitation Hospital of Bangor now open in Maine https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q3-2026-results-announcement BiopharmaWatch en 2026-10-06T20:30:00.000Z Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-lotte-biologics-manufacturing-agreement BiopharmaWatch en 2026-10-06T20:30:00.000Z Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply https://www.biopharmawatch.com/news/NVST/envista-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-06T20:15:00.000Z Envista Schedules Third Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-inducement-awards-20261006 BiopharmaWatch en 2026-10-06T20:15:00.000Z Crescent Biopharma Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-secures-credit-facility-150-million BiopharmaWatch en 2026-10-06T20:12:00.000Z Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital https://www.biopharmawatch.com/news/ARAY/accuray-stockholder-approval-financing-director BiopharmaWatch en 2026-10-06T20:10:00.000Z Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-evaluate-strategic-alternatives BiopharmaWatch en 2026-10-06T20:05:31.000Z Caribou Biosciences to Evaluate Strategic Alternatives https://www.biopharmawatch.com/news/QGEN/qiagen-ai-powered-bioinformatics-research-drug-discovery BiopharmaWatch en 2026-10-06T20:05:00.000Z QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery https://www.biopharmawatch.com/news/BFLY/bridge-neurotech-butterfly-network-partnership-bci BiopharmaWatch en 2026-10-06T20:05:00.000Z Bridge Neurotech and Butterfly Network Announce Partnership to Develop Fully Non-Invasive Brain-Computer Interface https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-mze829-mze782-asn-kidney-week-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/EQ/equillium-poster-presentation-la-jolla-immunology-conference BiopharmaWatch en 2026-10-06T20:05:00.000Z Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-scientific-advisory-board-creation BiopharmaWatch en 2026-10-06T20:05:00.000Z Harvard Bioscience Announces Creation of Scientific Advisory Board https://www.biopharmawatch.com/news/IVA/inventiva-abstracts-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Inventiva présentera plusieurs abstracts scientifiques lors de l’AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/IVA/inventiva-present-scientific-abstracts-aasld-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/HALO/halozyme-expands-collaboration-with-argenx-enhanze BiopharmaWatch en 2026-10-06T20:05:00.000Z Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-fda-alignment-enable-2-trial BiopharmaWatch en 2026-10-06T20:05:00.000Z Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia https://www.biopharmawatch.com/news/IMNM/immunome-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261006 BiopharmaWatch en 2026-10-06T20:02:00.000Z Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-granting-new-hire-inducement-awards BiopharmaWatch en 2026-10-06T20:02:00.000Z Achieve Life Sciences Announces Granting of New Hire Inducement Awards https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-hfsa-annual-meeting-2026 BiopharmaWatch en 2026-10-06T20:01:00.000Z BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 https://www.biopharmawatch.com/news/BBIO/bridgebio-present-evidence-phase-3-calibrate-trial-encaleret BiopharmaWatch en 2026-10-06T20:01:00.000Z BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/EVGN/evogene-pure-capital-agreement-board-reconstitution BiopharmaWatch en 2026-10-06T20:00:00.000Z Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors https://www.biopharmawatch.com/news/INAB/in8bio-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-06T20:00:00.000Z IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CDRE/veeva-dqs-nettoie-donnees-participants-etudes BiopharmaWatch en 2026-10-06T18:52:00.000Z Veeva DQS nettoie les données de plus d'un million de participants dans le cadre de plus de 1 000 études https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-announces-first-patient-dosed-phase-2a-reset-trial BiopharmaWatch en 2026-10-06T15:15:00.000Z Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value https://www.biopharmawatch.com/news/MDT/blink-anesthesia-lindsay-boyle-vp-commercial-operations BiopharmaWatch en 2026-10-06T14:18:00.000Z Blink Anesthesia, maker of the TwitchView® quantitative neuromuscular monitor, names Medtronic veteran Lindsay Boyle VP of Commercial Operations https://www.biopharmawatch.com/news/PFE/pfizer-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-06T14:00:00.000Z Pfizer Declares Fourth-Quarter 2026 Dividend https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-new-cfo-kevin-lundquist BiopharmaWatch en 2026-10-06T13:20:00.000Z Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-100-growth-cypath-lung-sales-through-third BiopharmaWatch en 2026-10-06T13:19:00.000Z bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 https://www.biopharmawatch.com/news/LEXX/glp-1-weight-loss-diabetes-transition-oral-medications BiopharmaWatch en 2026-10-06T13:15:24.000Z GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications https://www.biopharmawatch.com/news/ASND/ascendis-advances-hypoparathyroidism-achondroplasia-asbmr-2026 BiopharmaWatch en 2026-10-06T13:15:00.000Z Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-midwest-dental-agreement BiopharmaWatch en 2026-10-06T13:07:00.000Z Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement https://www.biopharmawatch.com/news/RGEN/repligen-acquisition-biolife-solutions BiopharmaWatch en 2026-10-06T13:05:00.000Z Repligen Completes Acquisition of BioLife Solutions https://www.biopharmawatch.com/news/NTHI/neonc-fda-catalyst-nthi-jolt BiopharmaWatch en 2026-10-06T13:02:00.000Z NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt https://www.biopharmawatch.com/news/DXCM/dexcom-u-season-5-record-roster-diabetes-stigma BiopharmaWatch en 2026-10-06T13:00:00.000Z Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading https://www.biopharmawatch.com/news/BDX/bdx-65-years-manufacturing-innovation-canaan BiopharmaWatch en 2026-10-06T13:00:00.000Z BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan https://www.biopharmawatch.com/news/CODX/co-diagnostics-showcase-codx-pcr-platform-ebola-assay BiopharmaWatch en 2026-10-06T13:00:00.000Z Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development https://www.biopharmawatch.com/news/PEN/storm-pe-data-wearable-technology-pulmonary-embolism BiopharmaWatch en 2026-10-06T13:00:00.000Z New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism https://www.biopharmawatch.com/news/GILD/cognizant-expands-ai-devops-gilead-sciences BiopharmaWatch en 2026-10-06T13:00:00.000Z Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences https://www.biopharmawatch.com/news/INMB/inmune-bio-attend-2026-maxim-growth-summit BiopharmaWatch en 2026-10-06T13:00:00.000Z INmune Bio to Attend the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/MDLN/medline-third-quarter-2026-results-report BiopharmaWatch en 2026-10-06T13:00:00.000Z Medline to report third quarter 2026 results on November 4, 2026 https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-presentation-nature-conference BiopharmaWatch en 2026-10-06T12:55:00.000Z Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center https://www.biopharmawatch.com/news/HYFT/mindwalk-biological-context-layer-ai-hyft BiopharmaWatch en 2026-10-06T12:46:00.000Z MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function https://www.biopharmawatch.com/news/DWTX/dogwood-participate-2026-maxim-growth-summit BiopharmaWatch en 2026-10-06T12:45:00.000Z Dogwood to Participate in the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-ld-micro-20th-annual-event BiopharmaWatch en 2026-10-06T12:32:00.000Z Niagen Bioscience to Present at LD Micro 20th Annual Main Event https://www.biopharmawatch.com/news/OSTX/ost-therapies-phase-2b-trial-results BiopharmaWatch en 2026-10-06T12:30:00.000Z OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial https://www.biopharmawatch.com/news/ACOG/alpha-cognition-present-zunveyl-data-ascp-meeting BiopharmaWatch en 2026-10-06T12:30:00.000Z Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress https://www.biopharmawatch.com/news/HSCS/heartsciences-fda-clearance-myvista-wavecg-device BiopharmaWatch en 2026-10-06T12:30:00.000Z HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-2026-financial-results-call BiopharmaWatch en 2026-10-06T12:30:00.000Z Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-fda-510k-submission-update BiopharmaWatch en 2026-10-06T12:30:00.000Z Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission https://www.biopharmawatch.com/news/MBOT/microbot-medical-medtechnica-distribution-agreement-israel BiopharmaWatch en 2026-10-06T12:30:00.000Z Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel https://www.biopharmawatch.com/news/MDAI/spectral-ai-ntap-application-deepview-system BiopharmaWatch en 2026-10-06T12:30:00.000Z Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System https://www.biopharmawatch.com/news/ICCM/icecure-expands-choices-study-low-risk-breast-cancer BiopharmaWatch en 2026-10-06T12:25:00.000Z IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-wins-marie-claire-beauty-award BiopharmaWatch en 2026-10-06T12:20:26.000Z Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-data-readout BiopharmaWatch en 2026-10-06T12:10:00.000Z 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA https://www.biopharmawatch.com/news/RKTO/rocket-one-patent-license-agreement-us-air-force BiopharmaWatch en 2026-10-06T12:05:00.000Z Rocket One Signs Patent License Agreement with U.S. Air Force for Technology Designed to Capture and Neutralize Hostile Drones https://www.biopharmawatch.com/news/ENTX/entera-appoints-laura-hamill-board-directors BiopharmaWatch en 2026-10-06T12:00:00.000Z Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise https://www.biopharmawatch.com/news/COLL/collegium-start-talking-adhd-support-resources BiopharmaWatch en 2026-10-06T12:00:00.000Z Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life https://www.biopharmawatch.com/news/PDSB/pds-biotech-kol-event-pds0301-colorectal-cancer BiopharmaWatch en 2026-10-06T12:00:00.000Z PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases https://www.biopharmawatch.com/news/OABI/omniab-partner-pipeline-xploration-outlook BiopharmaWatch en 2026-10-06T12:00:00.000Z OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day https://www.biopharmawatch.com/news/NTRA/natera-signatera-data-astro-conference-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists https://www.biopharmawatch.com/news/CRL/charles-river-autolomous-laboratory-execution-systems BiopharmaWatch en 2026-10-06T12:00:00.000Z Charles River and Autolomous Partner to Transform Laboratory Execution Systems https://www.biopharmawatch.com/news/AMLX/amylyx-phase-3-lucidity-trial-avexitide-obesityweek-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting https://www.biopharmawatch.com/news/RVTY/revvity-host-investor-day-november-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Revvity to Host Investor Day https://www.biopharmawatch.com/news/MCK/cdr-mckesson-acquire-option-care-health BiopharmaWatch en 2026-10-06T12:00:00.000Z CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health https://www.biopharmawatch.com/news/ENSG/diversified-healthcare-trust-ensign-group-lease-colorado BiopharmaWatch en 2026-10-06T12:00:00.000Z Diversified Healthcare Trust Announces 15-Year Net Lease with The Ensign Group for Colorado Skilled Nursing Portfolio https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-stk-002-aao-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting https://www.biopharmawatch.com/news/TRLV/trulieve-q3-2026-results-conference-call BiopharmaWatch en 2026-10-06T12:00:00.000Z Trulieve Cannabis Corp. to Hold Third Quarter 2026 Results Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/AVBP/arivent-phase-3-furvent-trial-update-firmonertinib BiopharmaWatch en 2026-10-06T12:00:00.000Z ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-efficacy-mash-genetic-variants BiopharmaWatch en 2026-10-06T12:00:00.000Z Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-voice-trial-asn-kidney-week-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-rd-day-lb-102-schizophrenia BiopharmaWatch en 2026-10-06T12:00:00.000Z LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-ai-cancer-risk-assessment BiopharmaWatch en 2026-10-06T12:00:00.000Z YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-kol-event-hypoglycemia-type-1-diabetes BiopharmaWatch en 2026-10-06T12:00:00.000Z vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-phase-2a-od-001-ueg-week-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-secures-financing-dejoria-investment BiopharmaWatch en 2026-10-06T12:00:00.000Z Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company https://www.biopharmawatch.com/news/SYK/stryker-leadership-succession-announcement BiopharmaWatch en 2026-10-06T12:00:00.000Z Stryker announces leadership succession https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-expanded-coverage-zelsuvmi BiopharmaWatch en 2026-10-06T12:00:00.000Z Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% https://www.biopharmawatch.com/news/BBIO/bridgebio-fda-acceptance-priority-review-infigratinib BiopharmaWatch en 2026-10-06T11:30:00.000Z BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia https://www.biopharmawatch.com/news/KAPA/kairos-pharma-phase-2-trial-env-105-prostate-cancer BiopharmaWatch en 2026-10-06T11:30:00.000Z Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer https://www.biopharmawatch.com/news/DRIO/dariohealth-aon-analysis-healthcare-cost-reduction BiopharmaWatch en 2026-10-06T11:30:00.000Z DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-webcast-q3-2026-results BiopharmaWatch en 2026-10-06T11:30:00.000Z Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BCTX/briacell-briapro-sitc-2026-poster-presentations BiopharmaWatch en 2026-10-06T11:30:00.000Z BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/CNSY/cerenome-launches-cnside-csf-molecular-profile-tests BiopharmaWatch en 2026-10-06T11:30:00.000Z Cerenome Launches CNSide® CSF Molecular Profile Tests https://www.biopharmawatch.com/news/SCYX/scynexis-phase-1-study-results-scy-770-adpkd BiopharmaWatch en 2026-10-06T11:30:00.000Z SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-maintenance-dosing-trial BiopharmaWatch en 2026-10-06T11:05:00.000Z Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-ivana-rubino-cco BiopharmaWatch en 2026-10-06T11:05:00.000Z ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-virtual-rd-event-october-2026 BiopharmaWatch en 2026-10-06T11:05:00.000Z Zenas BioPharma to Host Virtual R&D Event https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-jolanda-crombach-european-affiliate BiopharmaWatch en 2026-10-06T11:02:00.000Z Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-global-markets-virtual-forum-2026 BiopharmaWatch en 2026-10-06T11:00:00.000Z Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 https://www.biopharmawatch.com/news/REGN/regeneron-advances-cancer-care-esmo-2026 BiopharmaWatch en 2026-10-06T11:00:00.000Z Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 https://www.biopharmawatch.com/news/BRKR/draft-atlas-human-plasma-proteome BiopharmaWatch en 2026-10-06T11:00:00.000Z Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution https://www.biopharmawatch.com/news/BHC/bausch-health-third-quarter-2026-results BiopharmaWatch en 2026-10-06T11:00:00.000Z Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 https://www.biopharmawatch.com/news/CLGN/lightsolver-files-provisional-patent-photonic-computing BiopharmaWatch en 2026-10-06T11:00:00.000Z LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations https://www.biopharmawatch.com/news/CGEN/compugen-participate-fireside-chat-h-c-wainwright-3rd-annual-ai BiopharmaWatch en 2026-10-06T11:00:00.000Z Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-celebrates-dr-karl-deisseroth-nobel-prize BiopharmaWatch en 2026-10-06T11:00:00.000Z MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics https://www.biopharmawatch.com/news/OKYO/okyo-phase-3-trial-urcosimod-neuropathic-corneal-pain BiopharmaWatch en 2026-10-06T11:00:00.000Z OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain https://www.biopharmawatch.com/news/KMDA/kamada-expansion-biosimilars-portfolio-launch-products-israel BiopharmaWatch en 2026-10-06T11:00:00.000Z Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel https://www.biopharmawatch.com/news/BDX/bd-appoints-ferass-abuzaina-president-surgery BiopharmaWatch en 2026-10-06T10:50:00.000Z BD Appoints Ferass Abuzaina as Worldwide President of Surgery https://www.biopharmawatch.com/news/TLX/first-patients-dosed-telix-pixclara-brain-cancer BiopharmaWatch en 2026-10-06T10:30:00.000Z First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-qrx003-dermatology-therapy BiopharmaWatch en 2026-10-06T10:30:00.000Z Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy https://www.biopharmawatch.com/news/MNOV/medicinova-participate-maxim-growth-summit BiopharmaWatch en 2026-10-06T10:00:00.000Z MediciNova to Participate in the Maxim Growth Summit https://www.biopharmawatch.com/news/JAGX/napo-pharmaceuticals-sponsoring-intestinal-failure-panel BiopharmaWatch en 2026-10-06T09:00:00.000Z Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi https://www.biopharmawatch.com/news/SNN/smith-nephew-launch-cartiheal-agili-c-europe BiopharmaWatch en 2026-10-06T08:00:00.000Z Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo. https://www.biopharmawatch.com/news/SNN/smith-nephew-cartilage-repair-implant-launch-europe BiopharmaWatch en 2026-10-06T08:00:00.000Z Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal https://www.biopharmawatch.com/news/MBX/microbix-presentation-cantech-investment-conference BiopharmaWatch en 2026-10-06T07:00:00.000Z Microbix Presenting at Cantech Investment Conference https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-symon-ii-clinical-dataset-sepsis BiopharmaWatch en 2026-10-06T06:30:00.000Z Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock https://www.biopharmawatch.com/news/TMO/thermo-fisher-new-solutions-cphi-milan-2026 BiopharmaWatch en 2026-10-06T06:00:00.000Z Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-350-million-public-offering BiopharmaWatch en 2026-10-06T00:13:00.000Z Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T22:00:00.000Z Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-inducement-award-nasdaq-rule-5635 BiopharmaWatch en 2026-10-05T21:00:00.000Z Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PCVX/vaxcyte-public-offering-common-stock-notes BiopharmaWatch en 2026-10-05T20:28:00.000Z Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes https://www.biopharmawatch.com/news/EQ/equillium-australian-regulatory-clearance-eq504-trial BiopharmaWatch en 2026-10-05T20:05:00.000Z Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 https://www.biopharmawatch.com/news/AGL/agilon-health-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-05T20:05:00.000Z agilon health Sets Date to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VIR/vir-biotechnology-expanded-phase-2-results-hepatitis-delta BiopharmaWatch en 2026-10-05T20:05:00.000Z Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 https://www.biopharmawatch.com/news/NEO/neogenomics-executive-leadership-succession-plan BiopharmaWatch en 2026-10-05T20:05:00.000Z NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-cara-bauer-chief-people-officer BiopharmaWatch en 2026-10-05T20:05:00.000Z BioMarin Appoints Cara Bauer as Chief People Officer https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-kidney-week-2026 BiopharmaWatch en 2026-10-05T20:05:00.000Z Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting https://www.biopharmawatch.com/news/KRRO/korro-phase-1-2-trial-krro-121 BiopharmaWatch en 2026-10-05T20:05:00.000Z Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 https://www.biopharmawatch.com/news/LAB/standard-bi-tools-sells-microfluidics-business-archimed BiopharmaWatch en 2026-10-05T20:05:00.000Z Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q3-2026-financial-results BiopharmaWatch en 2026-10-05T20:05:00.000Z Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-bob-ragusa-board-appointment BiopharmaWatch en 2026-10-05T20:05:00.000Z Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-abstracts-liver-meeting-2026 BiopharmaWatch en 2026-10-05T20:05:00.000Z Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T20:02:00.000Z Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BBIO/bridgebio-education-effort-attr-cm-awareness BiopharmaWatch en 2026-10-05T20:01:00.000Z BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day https://www.biopharmawatch.com/news/NGNE/neurogene-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261005 BiopharmaWatch en 2026-10-05T20:01:00.000Z Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GRAL/grail-new-data-nhs-galleri-pathfinder-2-edcc-esmo-2026 BiopharmaWatch en 2026-10-05T20:01:00.000Z GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-agreement-cancer-research-uk BiopharmaWatch en 2026-10-05T20:01:00.000Z ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development https://www.biopharmawatch.com/news/CABA/cabaletta-bio-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-05T20:01:00.000Z Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-proposed-public-offering-common-stock BiopharmaWatch en 2026-10-05T20:01:00.000Z Spyre Therapeutics Announces Proposed Public Offering of its Common Stock https://www.biopharmawatch.com/news/ABBV/abbvie-genmab-announce-epcoritamab-combination-r-chop-demonstrates-significant-improvement BiopharmaWatch en 2026-10-05T18:54:00.000Z AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/GMAB/genmab-abbvie-epcoritamab-r-chop-trial-results BiopharmaWatch en 2026-10-05T18:50:00.000Z Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/ABBV/epcoritamab-r-chop-dlbcl-trial-results BiopharmaWatch en 2026-10-05T18:49:00.000Z Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-share-buyback-completion-2026 BiopharmaWatch en 2026-10-05T16:30:00.000Z Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) https://www.biopharmawatch.com/news/AZN/astrazeneca-opens-new-rd-center-kendall-square BiopharmaWatch en 2026-10-05T16:01:00.000Z AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts https://www.biopharmawatch.com/news/HNGE/hinge-health-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-05T16:00:00.000Z Hinge Health to announce third quarter 2026 financial results on November 2, 2026 https://www.biopharmawatch.com/news/PRVA/anthem-blue-cross-privia-health-agreement-virginia BiopharmaWatch en 2026-10-05T15:49:00.000Z Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement